STXS Stereotaxis

Stereotaxis to Report Third Quarter Financial Results on November 10, 2022

Stereotaxis to Report Third Quarter Financial Results on November 10, 2022

ST. LOUIS, Oct. 20, 2022 (GLOBE NEWSWIRE) -- (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it will release financial results for its 2022 third quarter on Thursday, November 10, 2022 before the open of the U.S. financial markets. The Company will host a conference call and webcast at 10 a.m. EST that day to discuss the Company’s results and corporate developments.

What:Stereotaxis third quarter 2022 financial results conference call
  
When:Thursday, November 10, 2022, at 10:00 a.m. EST (7:00 a.m. PST)
  
Dial In Number:To access the live call, dial 800-715-9871 (US and Canada) or 1-646-307-1963 (International) and give the participant pass code 5729833.
  
Webcast:To access the live and replay webcast, please visit the investor relations section of Stereotaxis’ website at .
  
Call Replay:A phone replay of the call will be available for one month beginning approximately four hours following the end of the call. To request access for a replay of the conference call, please .
  

About Stereotaxis

(NYSE: STXS) is a pioneer and global leader in innovative surgical robotics for minimally invasive endovascular intervention. Its mission is the discovery, development and delivery of robotic systems, instruments, and information solutions for the interventional laboratory. These innovations help physicians provide unsurpassed patient care with robotic precision and safety, expand access to minimally invasive therapy, and enhance the productivity, connectivity, and intelligence in the operating room. Stereotaxis technology has been used to treat over 100,000 patients across the United States, Europe, Asia, and elsewhere. For more information, please visit .

Investor Contacts:

David L. Fischel

Chairman and Chief Executive Officer
Media Contact:

Bethanne Schluter

Director, Marketing & Communications
  
Kimberly Peery

Chief Financial Officer
 
  
314-678-6100

 


EN
20/10/2022

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Stereotaxis

 PRESS RELEASE

First US Commercial Robotic HD Mapping Procedures Successfully Complet...

First US Commercial Robotic HD Mapping Procedures Successfully Completed with MAGiC Sweep Catheter ST. LOUIS, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced the successful completion of the world’s first procedures using MAGiC Sweep™, the first and only robotically-navigated high-density electrophysiology (EP) mapping catheter. The procedures were performed by Dr. Raffaele Corbisiero and Dr. Pedram Kazemian at Deborah Heart and Lung Center in Browns Mills, New J...

 PRESS RELEASE

Stereotaxis to Present at Upcoming Investor Conferences

Stereotaxis to Present at Upcoming Investor Conferences ST. LOUIS, Sept. 02, 2025 (GLOBE NEWSWIRE) -- (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that David Fischel, Chairman and CEO, will present at two investor conferences in New York City in September. Mr. Fischel will present an overview of Stereotaxis business on Wednesday, September 10th, 2025, at 8:00 am EDT and will be available that same day for one-on-one meetings. Mr. Fischel will be available for one-on-one meetings on T...

 PRESS RELEASE

Stereotaxis Technology to be Featured at Heart Rhythm Society’s HRX 20...

Stereotaxis Technology to be Featured at Heart Rhythm Society’s HRX 2025 ST. LOUIS, Aug. 28, 2025 (GLOBE NEWSWIRE) -- (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced its technology will be featured during the upcoming HRX digital health conference taking place September 4-6, 2025, in Atlanta, Georgia. HRX, an initiative pioneered by the Heart Rhythm Society, is focused on exploring digital technologies that advance the frontiers of cardiovascular medicine. Stereotaxis CEO, David Fischel, will participate in...

 PRESS RELEASE

Stereotaxis Reports 2025 Second Quarter Financial Results

Stereotaxis Reports 2025 Second Quarter Financial Results ST. LOUIS, Aug. 07, 2025 (GLOBE NEWSWIRE) -- (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today reported financial results for the second quarter ended June 30, 2025. “We are pleased with our commercial results in the quarter. Sequential and year-over-year growth in both recurring and system revenue reflects the early positive impact of our innovations on commercial adoption,” said David Fischel, Chairman and CEO. “This is an exciting milestone rich year with bro...

 PRESS RELEASE

Stereotaxis Receives U.S. FDA Clearance for MAGiC Sweep Catheter

Stereotaxis Receives U.S. FDA Clearance for MAGiC Sweep Catheter ST. LOUIS, July 28, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it has received U.S. Food and Drug Administration (FDA) 510(k) clearance for its groundbreaking MAGiC Sweep™ catheter. MAGiC Sweep is the world’s first robotically navigated high-density electrophysiology (EP) mapping catheter, representing a significant advancement in the technology available to diagnose and treat complex arrhythmia pat...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch